Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ADMA Biologics, Inc. (ADMA)
USD8.80
-0.07 (-0.79%)
US NASDAQ Healthcare Biotechnology
Address
465 State Route 17 7446
Ramsey, NJ, US
Ramsey, NJ, US
CEO
Adam S. Grossman
Website
admabiologics.com
IPO
2013-10-17
CIK 1368514 ISIN US0008991046
Description
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
News Sentiment (7d)
53 articles
- INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit PRNewsWire
- Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm GlobeNewsWire
- ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA Newsfile Corp
- DEADLINE ALERT for BTGO, VIA, Z, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions Globe News Wire
- Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD8.80
-0.07 (-0.79%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.73
Float Shares
233.02M
Free Float %
100.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.55% | +4.65% | -18.76% | -49.45% | -52.13% | -56.80% | -61.47% | +86.73% | +371.86% | +34.70% | -7.84% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
8.80
Low
18.00
+104.5%
Consensus
21.00
+138.6%
Median
21.00
+138.6%
High
24.00
+172.7%
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
22.50
+155.7%
|
| Last Quarter | 2 |
22.50
+155.7%
|
| Last Year | 2 |
22.50
+155.7%
|
| All Time | 7 |
13.07
+48.5%
|
Quality scores
Altman Z-Score
6.46
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+19.6% ★ Q1'26: -0.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-25.9% Q1'26: +72.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+1.4% Q1'26: +48.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+37.2% ★ Q1'26: +43.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+32.5% ★ Q1'26: +35.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.6% ★ Q1'26: -1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.40× ★ Q1'26: 0.98× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.18M
est: 6.58M (+9.1%)
|
10.66M
est: 8.60M (+24.0%)
|
22.76M
est: 18.86M (+20.7%)
|
16.99M
est: 18.13M (-6.3%)
|
29.35M
est: 26.74M (+9.8%)
|
42.22M
est: 41.07M (+2.8%)
|
80.94M
est: 76.24M (+6.2%)
|
154.08M
est: 151.48M (+1.7%)
|
258.22M
est: 330.24M (-21.8%)
|
426.45M
est: 421.67M (+1.1%)
|
510.17M
est: 510.60M (-0.1%)
|
570.08M
540.24M – 607.76M
+11.6% YoY
|
689.36M
653.27M – 734.92M
+20.9% YoY
|
823.30M
804.93M – 841.67M
+19.4% YoY
|
970.13M
919.34M – 1.03B
+17.8% YoY
|
1.08B
1.02B – 1.15B
+10.9% YoY
|
| EBITDA |
-15.66M
est: -2.03M (-669.6%)
|
-16.81M
est: -14.79M (-13.6%)
|
-39.31M
est: -5.83M (-573.9%)
|
-56.77M
est: -5.61M (-912.6%)
|
-36.03M
est: -8.27M (-335.7%)
|
-59.82M
est: -12.70M (-371.0%)
|
-53.10M
est: -23.58M (-125.2%)
|
-39.51M
est: -45.82M (+13.8%)
|
5.12M
est: -10.46M (+148.9%)
|
147.69M
est: -13.36M (+1,205.5%)
|
197.86M
est: -16.18M (+1,323.1%)
|
-18.06M
-19.26M – -17.12M
-11.6% YoY
|
-21.84M
-23.28M – -20.70M
-20.9% YoY
|
-26.08M
-26.67M – -25.50M
-19.4% YoY
|
-30.74M
-32.77M – -29.13M
-17.8% YoY
|
-34.09M
-36.34M – -32.30M
-10.9% YoY
|
| EBIT |
-16.13M
est: -2.25M (-616.2%)
|
-17.28M
est: -15.26M (-13.2%)
|
-40.47M
est: -6.46M (-526.9%)
|
-60.22M
est: -6.21M (-870.4%)
|
-39.29M
est: -9.15M (-329.2%)
|
-63.76M
est: -14.06M (-353.5%)
|
-58.59M
est: -26.10M (-124.5%)
|
-46.63M
est: -47.16M (+1.1%)
|
-3.21M
est: -22.42M (+85.7%)
|
139.64M
est: -28.63M (+587.8%)
|
189.77M
est: -34.67M (+647.4%)
|
-38.71M
-41.26M – -36.68M
-11.6% YoY
|
-46.80M
-49.90M – -44.35M
-20.9% YoY
|
-55.90M
-57.15M – -54.65M
-19.4% YoY
|
-65.87M
-70.22M – -62.42M
-17.8% YoY
|
-73.05M
-77.88M – -69.23M
-10.9% YoY
|
| Net Income |
-17.97M
est: -417.57M (+95.7%)
|
-19.52M
est: -17.27M (-13.0%)
|
-43.76M
est: -466.00M (+90.6%)
|
-65.74M
est: -339.06M (+80.6%)
|
-48.28M
est: -215.97M (+77.6%)
|
-75.75M
est: -205.02M (+63.1%)
|
-71.65M
est: -124.87M (+42.6%)
|
-65.90M
est: -40.29M (-63.6%)
|
-28.24M
est: 37.68M (-175.0%)
|
197.67M
est: 125.72M (+57.2%)
|
146.93M
est: 144.55M (+1.6%)
|
206.54M
199.16M – 213.91M
+42.9% YoY
|
284.30M
246.49M – 287.22M
+37.7% YoY
|
360.23M
284.47M – 383.81M
+26.7% YoY
|
417.15M
388.76M – 453.00M
+15.8% YoY
|
487.36M
454.19M – 529.23M
+16.8% YoY
|
| SGA |
6.75M
est: 2.77M (+143.8%)
|
8.49M
est: 7.70M (+10.3%)
|
18.09M
est: 7.93M (+128.1%)
|
22.50M
est: 7.63M (+195.1%)
|
25.91M
est: 11.25M (+130.4%)
|
35.05M
est: 17.28M (+102.9%)
|
42.90M
est: 32.07M (+33.8%)
|
52.46M
est: 35.01M (+49.8%)
|
59.02M
est: 95.92M (-38.5%)
|
74.12M
est: 122.48M (-39.5%)
|
91.58M
est: 148.31M (-38.3%)
|
165.59M
156.92M – 176.53M
+11.6% YoY
|
200.23M
189.75M – 213.47M
+20.9% YoY
|
239.14M
233.80M – 244.47M
+19.4% YoY
|
281.79M
267.03M – 300.41M
+17.8% YoY
|
312.53M
296.17M – 333.18M
+10.9% YoY
|
| EPS |
-1.73
est: -1.72 (-0.8%)
|
-1.61
est: -1.60 (-0.9%)
|
-1.91
est: -1.92 (+0.3%)
|
-1.45
est: -1.39 (-4.1%)
|
-1.05
est: -0.89 (-18.3%)
|
-1.02
est: -0.84 (-21.1%)
|
-0.61
est: -0.51 (-18.9%)
|
-0.43
est: -0.33 (-30.3%)
|
-0.13
est: 0.15 (-185.3%)
|
0.85
est: 0.51 (+65.6%)
|
0.62
est: 0.59 (+6.0%)
|
0.84
0.81 – 0.87
+44.2% YoY
|
1.08
1.01 – 1.17
+28.1% YoY
|
1.38
1.16 – 1.57
+27.5% YoY
|
1.70
1.59 – 1.85
+23.7% YoY
|
1.99
1.85 – 2.16
+16.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
121.50M
OE per share TTM
0.50
Owner's Yield
5.11%
Maintenance CapEx ratio
5.79%
Maint CapEx / Avg PPE
26.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
85
Total invested
91.30M
Insider transactions (90d)
0
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 16,084,802 | 16.08M | 19.40% | — | 16.08M | — | 16.08M | IN | Delaware | 2020-02-14 | ↗ |
| 2 | 19.4% | 16.08M | 19.40% | — | 16.08M | — | 16.08M | CO | Delaware | 2020-02-14 | ↗ |
| 3 | (1) BlackRock, Inc. | 15.10M | 6.90% | 14.67M | — | 15.10M | — | HC | Delaware | 2023-02-03 | ↗ |
| 4 | STATE STREET CORPORATION | 13.00M | 5.60% | — | 12.20M | — | — | HC | MA | 2024-10-17 | ↗ |
| 5 | The Vanguard Group - 23-1945930 | 12.89M | 5.71% | — | — | 12.40M | 489.3K | IA | Pennsylvania | 2024-02-13 | ↗ |
| 6 | 98-0557567 | 12.79M | 5.50% | 12.03M | — | 12.62M | — | IA, HC | Bermuda | 2024-11-08 | ↗ |
| 7 | Joseph Edelman | 11.93M | 6.60% | — | 11.93M | — | 11.93M | IN | — | 2021-10-27 | ↗ |
| 8 | Perceptive Life Sciences Master Fund, Ltd. | 11.93M | 6.60% | — | 11.93M | — | 11.93M | CO | — | 2021-10-27 | ↗ |
| 9 | Perceptive Advisors LLC | 11.93M | 6.10% | — | 11.93M | — | 11.93M | IA | Delaware | 2022-02-15 | ↗ |
| 10 | Caligan Partners LP | 10.89M | 5.60% | — | 10.89M | — | 10.00 | IA, PN | Delaware | 2022-02-04 | ↗ |
| 11 | David Johnson | 10.89M | 5.60% | — | 10.89M | — | 10.00 | IN | United States | 2022-02-04 | ↗ |
| 12 | NWQ Investment Management Company, LLC | 10.61M | 5.42% | 10.61M | — | 10.61M | — | IA | U.S.A. | 2022-02-11 | ↗ |
| 13 | Jon M. Plexico | 9.91M | 11.00% | 9.91M | — | 9.91M | — | HC, IN | California | 2022-02-14 | ↗ |
| 14 | Stonepine Capital Management, LLC | 9.91M | 11.00% | 9.91M | — | 9.91M | — | IA, OO | California | 2022-02-14 | ↗ |
| 15 | Stonepine Capital, L.P. | 9.91M | 11.00% | 9.91M | — | 9.91M | — | PN | California | 2022-02-14 | ↗ |
| 16 | Timothy P. Lynch | 9.91M | 11.00% | 9.91M | — | 9.91M | — | HC, IN | California | 2022-02-14 | ↗ |
| 17 | Nuveen Asset Management, LLC | 5.06M | 2.24% | 5.06M | — | 5.06M | — | IA | Delaware | 2024-02-14 | ↗ |
| 18 | TIAA-CREF Investment Management, LLC | 4.08M | 1.80% | 4.08M | — | 4.08M | — | IA | Delaware | 2024-02-14 | ↗ |
| 19 | Teachers Advisors, LLC | 2.22M | 0.98% | 2.22M | — | 2.22M | — | IA | Delaware | 2024-02-14 | ↗ |
| 20 | Consonance Capman GP LLC | 1.56M | 1.65% | — | 1.56M | — | — | HC, OO | Delaware, USA | 2021-02-16 | ↗ |
| 21 | Mitchell Blutt | 1.56M | 1.65% | — | 1.56M | — | — | HC, IN | Delaware, USA | 2021-02-16 | ↗ |
| 22 | Israel A. Englander | 1.37M | 0.60% | — | 1.37M | — | 1.37M | IN | Delaware | 2024-09-23 | ↗ |
| 23 | Millennium Group Management LLC | 1.37M | 0.60% | — | 1.37M | — | 1.37M | OO | Delaware | 2024-09-23 | ↗ |
| 24 | Millennium Management LLC | 1.37M | 0.60% | — | 1.37M | — | 1.37M | OO | Delaware | 2024-09-23 | ↗ |
| 25 | Consonance Capital Management LP | 1.29M | 1.36% | — | 1.29M | — | 1.29M | IA, PN | Delaware USA | 2022-02-14 | ↗ |
| 26 | Consonance Capital Opportunity Fund Management LP | 268.8K | 0.28% | — | 268.8K | — | — | IA, PN | Delaware, USA | 2021-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
85
-286 vs prev Q
New positions
10
Closed positions
283
Increased
38
Reduced
29
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 1.55M +1.6M (+100.0%) | 28.29B +28.3B (+100.0%) | 0.65% +0.650 pp | 0.04% +0.043 pp | USD18.24 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 36.33M +701.6K (+2.0%) | 662.72M +140.4M (+26.9%) | 15.23% +0.473 pp | 0.01% +0.002 pp | USD19.96 -8.6% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 20.85M -120.3K (-0.6%) | 380.39M +72.9M (+23.7%) | 8.74% +0.055 pp | 0.01% +0.001 pp | USD9.45 +93.0% | 43 qtrs — |
| 4 | STATE STREET CORP | 13.60M +35.6K (+0.3%) | 248.01M +49.2M (+24.7%) | 5.70% +0.083 pp | 0.01% +0.001 pp | USD11.31 +61.3% | 31 qtrs — |
| 5 | INVESCO LTD. | 11.79M -720.3K (-5.8%) | 214.96M +31.6M (+17.3%) | 4.94% -0.239 pp | 0.03% +0.004 pp | USD8.52 +114.1% | 17 qtrs — |
| 6 | SACHEM HEAD CAPITAL MANAGEMENT LP | 11.38M +2.4M (+27.0%) | 207.48M +76.1M (+58.0%) | 4.77% +1.057 pp | 4.86% +1.154 pp | USD15.42 +18.3% | 2 qtrs — |
| 7 | WESTFIELD CAPITAL MANAGEMENT CO LP | 6.99M +1.9M (+36.9%) | 127.55M +52.7M (+70.4%) | 2.93% +0.816 pp | 0.53% +0.217 pp | USD15.63 +16.7% | 2 qtrs — |
| 8 | CAPITAL RESEARCH GLOBAL INVESTORS | 6.64M +3.4M (+104.0%) | 121.07M +73.4M (+153.8%) | 2.78% +1.434 pp | 0.02% +0.013 pp | USD16.48 +10.7% | 2 qtrs — |
| 9 | NUVEEN, LLC | 5.93M +202.2K (+3.5%) | 108.10M +24.2M (+28.8%) | 2.48% +0.113 pp | 0.03% +0.006 pp | USD19.41 -6.0% | 4 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 5.83M +17.2K (+0.3%) | 106.37M +21.1M (+24.8%) | 2.44% +0.036 pp | 0.01% +0.001 pp | USD5.34 +241.6% | 38 qtrs — |
| 11 | AMERICAN CENTURY COMPANIES INC | 5.20M +502.5K (+10.7%) | 94.82M +26.0M (+37.7%) | 2.18% +0.234 pp | 0.05% +0.013 pp | USD7.97 +128.9% | 12 qtrs — |
| 12 | DIMENSIONAL FUND ADVISORS LP | 4.84M +37.4K (+0.8%) | 88.20M +17.9M (+25.4%) | 2.03% +0.040 pp | 0.02% +0.003 pp | USD9.22 +97.8% | 22 qtrs — |
| 13 | UBS GROUP AG | 4.57M +2.6M (+129.9%) | 83.34M +54.2M (+186.0%) | 1.92% +1.092 pp | 0.01% +0.009 pp | USD17.80 +2.5% | 34 qtrs — |
| 14 | JANUS HENDERSON GROUP PLC | 3.94M +3.8M (+3,906.1%) | 71.82M +70.4M (+4,887.4%) | 1.65% +1.609 pp | 0.03% +0.032 pp | USD18.12 +0.7% | 13 qtrs — |
| 15 | THRIVENT FINANCIAL FOR LUTHERANS | 3.79M -351.3K (-8.5%) | 69.14M +8.4M (+13.9%) | 1.59% -0.127 pp | 0.12% +0.003 pp | USD18.24 +0.0% | 6 qtrs — |
| 16 | CALIGAN PARTNERS LP | 3.01M +375.9K (+14.3%) | 54.95M +16.3M (+42.2%) | 1.26% +0.171 pp | 4.52% -0.539 pp | USD15.11 +20.7% | 2 qtrs — |
| 17 | FRANKLIN RESOURCES INC | 2.79M -44.3K (-1.6%) | 50.96M -53.3M (-51.1%) | 1.17% -0.004 pp | 0.01% -0.014 pp | USD18.13 +0.6% | 11 qtrs — |
| 18 | B GROUP, INC. | 2.46M +45.0K (+1.9%) | 44.83M +9.5M (+26.7%) | 1.03% +0.031 pp | 33.10% +7.082 pp | USD17.11 +6.6% | 5 qtrs — |
| 19 | RANGER INVESTMENT MANAGEMENT, L.P. | 2.30M -39.8K (-1.7%) | 41.97M +7.7M (+22.3%) | 0.96% -0.005 pp | 2.88% +0.486 pp | USD19.30 -5.5% | 4 qtrs — |
| 20 | NORTHERN TRUST CORP | 2.27M -93.9K (-4.0%) | 41.35M +6.7M (+19.5%) | 0.95% -0.028 pp | 0.01% +0.001 pp | USD5.99 +204.5% | 36 qtrs — |
| 21 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.26M -103.1K (-4.4%) | 41.18M +6.6M (+19.0%) | 0.95% -0.031 pp | 0.01% +0.001 pp | USD6.85 +166.3% | 31 qtrs — |
| 22 | AWM INVESTMENT COMPANY, INC. | 2.20M +— (+0.0%) | 40.13M +7.9M (+24.4%) | 0.92% +0.011 pp | 3.88% +0.851 pp | USD1.86 +880.6% | 17 qtrs — |
| 23 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.16M +4.9K (+0.2%) | 39.41M +7.8M (+24.7%) | 0.91% +0.013 pp | 0.00% +0.001 pp | USD11.58 +57.5% | 15 qtrs — |
| 24 | FUNDSMITH LLP | 2.10M +2.1M (+100.0%) | 38.34M +38.3M (+100.0%) | 0.88% +0.881 pp | 0.22% +0.224 pp | USD18.24 +0.0% | 1 qtrs NEW |
| 25 | VOYA INVESTMENT MANAGEMENT LLC | 2.01M +557.9K (+38.4%) | 36.70M +15.4M (+72.2%) | 0.84% +0.241 pp | 0.04% +0.015 pp | USD16.02 +13.9% | 15 qtrs — |
| 26 | MORGAN STANLEY | 1.95M +490.2K (+33.6%) | 35.54M +14.2M (+66.2%) | 0.82% +0.213 pp | 0.00% +0.001 pp | USD13.37 +36.4% | 45 qtrs — |
| 27 | BANK OF AMERICA CORP /DE/ | 1.93M +801.7K (+71.3%) | 35.14M +18.6M (+113.1%) | 0.81% +0.342 pp | 0.00% +0.001 pp | USD16.63 +9.7% | 32 qtrs — |
| 28 | DEUTSCHE BANK AG\ | 1.82M +105.0K (+6.1%) | 33.25M +8.1M (+32.0%) | 0.76% +0.053 pp | 0.01% +0.002 pp | USD9.11 +100.2% | 31 qtrs — |
| 29 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.56M +489.7K (+45.7%) | 28.49M +12.8M (+81.2%) | 0.65% +0.211 pp | 0.00% +0.002 pp | USD15.92 +14.6% | 24 qtrs — |
| 30 | RENAISSANCE TECHNOLOGIES LLC | 1.53M -1.2M (-44.7%) | 27.96M -12.7M (-31.2%) | 0.64% -0.505 pp | 0.04% -0.010 pp | USD10.39 +75.6% | 19 qtrs — |
| 31 | CITADEL ADVISORS LLC | 1.52M -596.6K (-28.2%) | 27.77M -3.3M (-10.6%) | 0.64% -0.239 pp | 0.00% -0.001 pp | USD14.66 +24.4% | 27 qtrs — |
| 32 | PRINCIPAL FINANCIAL GROUP INC | 1.40M +80.3K (+6.1%) | 25.60M +6.2M (+32.0%) | 0.59% +0.040 pp | 0.01% +0.003 pp | USD18.10 +0.8% | 23 qtrs — |
| 33 | BANK OF NEW YORK MELLON CORP | 1.40M -20.2K (-1.4%) | 25.59M +4.7M (+22.7%) | 0.59% -0.001 pp | 0.00% +0.001 pp | USD11.39 +60.1% | 35 qtrs — |
| 34 | METLIFE INVESTMENT MANAGEMENT, LLC | 1.38M +71.6K (+5.5%) | 25.20M +6.0M (+31.2%) | 0.58% +0.037 pp | 0.12% +0.030 pp | USD14.85 +22.8% | 15 qtrs — |
| 35 | PFM HEALTH SCIENCES, LP | 1.27M +89.9K (+7.6%) | 23.18M +5.9M (+33.9%) | 0.53% +0.044 pp | 2.31% +0.980 pp | USD14.91 +22.3% | 2 qtrs — |
| 36 | ROYCE & ASSOCIATES LP | 1.23M +302.4K (+32.4%) | 22.52M +8.9M (+64.8%) | 0.52% +0.131 pp | 0.23% +0.092 pp | USD17.38 +4.9% | 5 qtrs — |
| 37 | BNP PARIBAS ARBITRAGE, SNC | 1.14M +1.1M (+2,188.4%) | 20.81M +20.1M (+2,747.2%) | 0.48% +0.458 pp | 0.01% +0.009 pp | USD17.92 +1.8% | 28 qtrs — |
| 38 | NEXT CENTURY GROWTH INVESTORS LLC | 1.10M +705.2K (+178.3%) | 20.08M +14.3M (+246.2%) | 0.46% +0.298 pp | 1.39% +0.972 pp | USD16.95 +7.6% | 2 qtrs — |
| 39 | GOLDMAN SACHS GROUP INC | 1.07M -1.8M (-63.3%) | 19.51M -23.2M (-54.3%) | 0.45% -0.757 pp | 0.00% -0.003 pp | USD14.24 +28.1% | 33 qtrs — |
| 40 | RUSSELL INVESTMENTS GROUP, LTD. | 1.06M -181.1K (-14.6%) | 19.27M +1.1M (+6.2%) | 0.44% -0.070 pp | 0.02% +0.000 pp | USD14.69 +24.2% | 12 qtrs — |
| 41 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.02M +1.0M (+100.0%) | 18.66M +18.7M (+100.0%) | 0.43% +0.429 pp | 0.07% +0.066 pp | USD18.24 +0.0% | 1 qtrs NEW |
| 42 | RAYMOND JAMES FINANCIAL INC | 1.01M -238.1K (-19.0%) | 18.49M +139.3K (+0.8%) | 0.42% -0.094 pp | 0.01% 0.000 pp | USD17.66 +3.3% | 5 qtrs — |
| 43 | ABRDN PLC | 963.9K -152.4K (-13.6%) | 17.58M +1.2M (+7.4%) | 0.40% -0.058 pp | 0.03% +0.001 pp | USD16.35 +11.6% | 3 qtrs — |
| 44 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 890.9K +890.9K (+100.0%) | 16.25M +16.2M (+100.0%) | 0.37% +0.373 pp | 0.05% +0.045 pp | USD18.24 +0.0% | 1 qtrs NEW |
| 45 | PERCEPTIVE ADVISORS LLC | 883.5K -270.0K (-23.4%) | 16.11M -795.4K (-4.7%) | 0.37% -0.107 pp | 0.29% -0.201 pp | USD9.33 +95.5% | 39 qtrs — |
| 46 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 823.7K -107.1K (-11.5%) | 15.02M +1.4M (+10.1%) | 0.35% -0.040 pp | 0.05% +0.000 pp | USD18.88 -3.4% | 6 qtrs — |
| 47 | BOOTHBAY FUND MANAGEMENT, LLC | 788.4K +15.2K (+2.0%) | 14.38M +3.0M (+26.9%) | 0.33% +0.010 pp | 0.21% +0.050 pp | USD14.73 +23.8% | 2 qtrs — |
| 48 | STONEPINE CAPITAL MANAGEMENT, LLC | 740.0K +1.0K (+0.1%) | 13.50M +2.7M (+24.6%) | 0.31% +0.004 pp | 9.85% +1.047 pp | USD2.49 +632.5% | 17 qtrs — |
| 49 | KENNEDY CAPITAL MANAGEMENT LLC | 677.6K +133.4K (+24.5%) | 12.36M +4.4M (+54.9%) | 0.28% +0.059 pp | 0.26% +0.085 pp | USD13.53 +34.8% | 13 qtrs — |
| 50 | MILLENNIUM MANAGEMENT LLC | 669.7K +384.8K (+135.1%) | 12.21M +8.0M (+192.5%) | 0.28% +0.163 pp | 0.01% +0.003 pp | USD15.83 +15.2% | 27 qtrs — |
| 51 | LEGAL & GENERAL GROUP PLC | 663.4K -30.8K (-4.4%) | 12.10M +1.9M (+18.9%) | 0.28% -0.009 pp | 0.00% +0.000 pp | USD15.25 +19.6% | 15 qtrs — |
| 52 | BARCLAYS PLC | 649.1K +120.5K (+22.8%) | 11.84M +1.3M (+12.0%) | 0.27% +0.053 pp | 0.00% +0.000 pp | USD16.40 +11.2% | 32 qtrs — |
| 53 | HOLOCENE ADVISORS, LP | 629.3K +629.3K (+100.0%) | 11.48M +11.5M (+100.0%) | 0.26% +0.264 pp | 0.02% +0.024 pp | USD18.24 +0.0% | 1 qtrs NEW |
| 54 | RHUMBLINE ADVISERS | 613.3K -37.3K (-5.7%) | 11.19M +1.6M (+17.3%) | 0.26% -0.012 pp | 0.01% +0.001 pp | USD11.70 +55.9% | 15 qtrs — |
| 55 | CATALIO CAPITAL MANAGEMENT, LP | 564.5K -120.0K (-17.5%) | 10.30M +260.9K (+2.6%) | 0.24% -0.047 pp | 1.82% -0.035 pp | USD17.61 +3.6% | 5 qtrs — |
| 56 | D. E. SHAW & CO., INC. | 557.2K +224.5K (+67.5%) | 10.16M +5.3M (+108.4%) | 0.23% +0.096 pp | 0.01% +0.003 pp | USD10.03 +81.9% | 19 qtrs — |
| 57 | AMERIPRISE FINANCIAL INC | 552.0K +30.1K (+5.8%) | 10.07M +2.4M (+31.6%) | 0.23% +0.015 pp | 0.00% +0.001 pp | USD16.67 +9.4% | 15 qtrs — |
| 58 | TWO SIGMA INVESTMENTS, LP | 504.2K -393.9K (-43.9%) | 9.20M -4.0M (-30.1%) | 0.21% -0.161 pp | 0.01% -0.007 pp | USD4.15 +339.5% | 15 qtrs — |
| 59 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 490.1K -1.1M (-68.3%) | 8.76M -14.5M (-62.4%) | 0.21% -0.436 pp | 0.01% -0.023 pp | USD16.55 +10.2% | 14 qtrs — |
| 60 | RENAISSANCE GROUP LLC | 475.7K -40.9K (-7.9%) | 8.68M +1.1M (+14.6%) | 0.20% -0.015 pp | 0.35% +0.063 pp | USD17.02 +7.2% | 3 qtrs — |
| 61 | PEREGRINE CAPITAL MANAGEMENT LLC | 471.5K -59.1K (-11.1%) | 8.60M +821.9K (+10.6%) | 0.20% -0.022 pp | 0.26% +0.030 pp | USD7.65 +138.4% | 9 qtrs — |
| 62 | SWISS NATIONAL BANK | 470.6K +7.8K (+1.7%) | 8.58M +1.8M (+26.5%) | 0.20% +0.006 pp | 0.01% +0.001 pp | USD5.30 +244.2% | 13 qtrs — |
| 63 | MARATHON CAPITAL MANAGEMENT | 465.3K -1.3K (-0.3%) | 8.49M +1.6M (+24.1%) | 0.20% +0.002 pp | 1.83% +0.261 pp | USD17.36 +5.1% | 4 qtrs — |
| 64 | WELLS FARGO & COMPANY/MN | 411.1K +59.5K (+16.9%) | 7.50M +2.3M (+45.5%) | 0.17% +0.027 pp | 0.00% +0.000 pp | USD13.50 +35.1% | 33 qtrs — |
| 65 | UBS ASSET MANAGEMENT AMERICAS INC | 400.0K +9.2K (+2.4%) | 7.30M +1.6M (+27.3%) | 0.17% +0.006 pp | 0.00% +0.000 pp | USD13.56 +34.5% | 12 qtrs — |
| 66 | POINT72 ASSET MANAGEMENT, L.P. | 393.9K -928.1K (-70.2%) | 7.18M -12.2M (-62.9%) | 0.17% -0.382 pp | 0.01% -0.024 pp | USD14.66 +24.4% | 9 qtrs — |
| 67 | CHEVY CHASE TRUST HOLDINGS, LLC | 383.6K -11.0K (-2.8%) | 7.00M +1.2M (+20.9%) | 0.16% -0.003 pp | 0.02% +0.003 pp | USD14.66 +24.4% | 2 qtrs — |
| 68 | NEUBERGER BERMAN GROUP LLC | 381.8K -131.5K (-25.6%) | 6.96M -560.7K (-7.5%) | 0.16% -0.053 pp | 0.01% 0.000 pp | USD17.66 +3.3% | 4 qtrs — |
| 69 | TREXQUANT INVESTMENT LP | 370.8K -46.5K (-11.2%) | 6.76M +645.2K (+10.5%) | 0.16% -0.017 pp | 0.06% -0.003 pp | USD18.01 +1.3% | 7 qtrs — |
| 70 | KORNITZER CAPITAL MANAGEMENT INC /KS | 356.9K -3.1K (-0.9%) | 6.51M +1.2M (+23.3%) | 0.15% +0.001 pp | 0.14% +0.029 pp | USD15.10 +20.8% | 5 qtrs — |
| 71 | PRUDENTIAL FINANCIAL INC | 325.4K -116.5K (-26.4%) | 5.93M -542.8K (-8.4%) | 0.14% -0.047 pp | 0.01% -0.001 pp | USD13.14 +38.8% | 15 qtrs — |
| 72 | CAPTION MANAGEMENT, LLC | 312.5K +15.0K (+5.0%) | 5.70M +1.3M (+30.7%) | 0.13% +0.008 pp | 0.04% +0.005 pp | USD19.76 -7.7% | 4 qtrs — |
| 73 | AQR CAPITAL MANAGEMENT LLC | 306.2K +31.0K (+11.3%) | 5.59M +1.6M (+38.5%) | 0.13% +0.014 pp | 0.00% +0.000 pp | USD5.81 +213.9% | 14 qtrs — |
| 74 | FMR LLC | 302.2K -430.4K (-58.7%) | 5.51M -5.2M (-48.7%) | 0.13% -0.177 pp | 0.00% 0.000 pp | USD14.21 +28.4% | 14 qtrs — |
| 75 | FINDELL CAPITAL MANAGEMENT LLC | 300.0K +300.0K (+100.0%) | 5.47M +5.5M (+100.0%) | 0.13% +0.126 pp | 1.57% +1.574 pp | USD18.24 +0.0% | 1 qtrs NEW |
| 76 | JPMORGAN CHASE & CO | 299.1K -162.6K (-35.2%) | 5.46M -1.3M (-19.4%) | 0.13% -0.066 pp | 0.00% 0.000 pp | USD13.94 +30.8% | 32 qtrs — |
| 77 | LPL FINANCIAL LLC | 296.2K +93.4K (+46.1%) | 5.40M +2.4M (+81.7%) | 0.12% +0.040 pp | 0.00% +0.001 pp | USD17.14 +6.4% | 13 qtrs — |
| 78 | ALLIANCEBERNSTEIN L.P. | 294.6K +13.4K (+4.8%) | 5.37M +1.3M (+30.4%) | 0.12% +0.007 pp | 0.00% +0.000 pp | USD6.93 +163.2% | 15 qtrs — |
| 79 | CALAMOS ADVISORS LLC | 292.4K +159.5K (+120.0%) | 5.33M +3.4M (+173.7%) | 0.12% +0.068 pp | 0.02% +0.013 pp | USD14.22 +28.3% | 11 qtrs — |
| 80 | RICE HALL JAMES & ASSOCIATES, LLC | 291.9K -31.7K (-9.8%) | 5.32M +580.1K (+12.2%) | 0.12% -0.012 pp | 0.29% +0.034 pp | USD6.54 +178.9% | 8 qtrs — |
| 81 | RAFFERTY ASSET MANAGEMENT, LLC | 291.2K -65.0K (-18.2%) | 5.31M +89.6K (+1.7%) | 0.12% -0.026 pp | 0.02% +0.001 pp | USD12.41 +47.0% | 14 qtrs — |
| 82 | SEI INVESTMENTS CO | 289.5K -224.5K (-43.7%) | 5.28M -2.3M (-29.9%) | 0.12% -0.092 pp | 0.01% -0.003 pp | USD13.39 +36.2% | 13 qtrs — |
| 83 | JANE STREET GROUP, LLC | 276.5K -7.7K (-2.7%) | 5.04M +877.0K (+21.0%) | 0.12% -0.002 pp | 0.00% +0.000 pp | USD18.58 -1.8% | 6 qtrs — |
| 84 | VIDENT ADVISORY, LLC | 270.5K +52.7K (+24.2%) | 4.93M +1.7M (+54.5%) | 0.11% +0.023 pp | 0.04% +0.014 pp | USD18.06 +1.0% | 4 qtrs — |
| 85 | DUQUESNE FAMILY OFFICE LLC | 252.2K +252.2K (+100.0%) | 4.60M +4.6M (+100.0%) | 0.11% +0.106 pp | 0.10% +0.102 pp | USD18.24 +0.0% | 1 qtrs NEW |
| 86 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 246.8K +246.8K (+100.0%) | 4.50M +4.5M (+100.0%) | 0.10% +0.103 pp | 0.05% +0.049 pp | USD18.24 +0.0% | 4 qtrs — |
| 87 | ALGERT GLOBAL LLC | 237.0K +183.9K (+346.3%) | 4.32M +3.5M (+455.5%) | 0.10% +0.077 pp | 0.07% +0.054 pp | USD17.81 +2.4% | 10 qtrs — |
| 88 | IKARIAN CAPITAL, LLC | 234.9K +75.0K (+46.9%) | 4.28M +1.9M (+82.8%) | 0.10% +0.032 pp | 0.33% +0.098 pp | USD15.80 +15.4% | 2 qtrs — |
| 89 | SQUAREPOINT OPS LLC | 234.4K -4.6K (-1.9%) | 4.28M +771.7K (+22.0%) | 0.10% -0.001 pp | 0.00% +0.001 pp | USD17.15 +6.4% | 5 qtrs — |
| 90 | PICTON MAHONEY ASSET MANAGEMENT | 230.8K -133.2K (-36.6%) | 4.21M -1.1M (-21.1%) | 0.10% -0.054 pp | 0.03% -0.016 pp | USD18.70 -2.5% | 6 qtrs — |
| 91 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 225.1K -202.0 (-0.1%) | 4.11M +803.0K (+24.3%) | 0.09% +0.001 pp | 0.00% +0.001 pp | USD5.79 +215.0% | 15 qtrs — |
| 92 | HOMESTEAD ADVISERS CORP | 220.6K +22.1K (+11.1%) | 4.02M +1.1M (+38.3%) | 0.09% +0.010 pp | 0.11% +0.037 pp | USD16.76 +8.8% | 3 qtrs — |
| 93 | PFG INVESTMENTS, LLC | 214.0K -7.5K (-3.4%) | 3.90M +656.0K (+20.2%) | 0.09% -0.002 pp | 0.18% +0.015 pp | USD6.45 +182.8% | 12 qtrs — |
| 94 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 206.2K -45.7K (-18.1%) | 3.76M +62.0K (+1.7%) | 0.09% -0.018 pp | 0.01% +0.001 pp | USD16.45 +10.9% | 13 qtrs — |
| 95 | PARKMAN HEALTHCARE PARTNERS LLC | 200.0K +200.0K (+100.0%) | 3.65M +3.6M (+100.0%) | 0.08% +0.084 pp | 0.35% +0.347 pp | USD18.24 +0.0% | 1 qtrs NEW |
| 96 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 197.0K -14.8K (-7.0%) | 3.59M +488.0K (+15.7%) | 0.08% -0.005 pp | 0.01% +0.001 pp | USD19.63 -7.1% | 6 qtrs — |
| 97 | DEKABANK DEUTSCHE GIROZENTRALE | 236.2K +— (+0.0%) | 1.70M +17.0K (+1.0%) | 0.10% +0.001 pp | 0.00% +0.000 pp | USD4.46 +309.0% | 10 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 157 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | First Trust NYSE Arca Biotechnology UCITS ETF FBTU.L | 2.72% | 384.1K | 0.60% |
| 2 | First Trust NYSE Arca Biotechnology Index Fund FBT | 2.51% | 70.70M | 0.55% |
| 3 | Virtus Biotech ETF BBP | 1.43% | 1.40M | 0.34% |
| 4 | Motley Fool Small-Cap Growth ETF TMFS | 1.40% | 882.1K | 0.85% |
| 5 | Invesco S&P SmallCap Health Care ETF PSCH | 0.92% | 1.50M | 0.29% |
| 6 | Global X - S&P Biotech ETF CURE.AX | 0.66% | 235.5K | 0.45% |
| 7 | State Street SPDR S&P Biotech ETF XBI | 0.66% | 70.95M | 0.35% |
| 8 | Research Affiliates Deletions ETF NIXT | 0.40% | 139.4K | 0.09% |
| 9 | Pacer US Small Cap Cash Cows Growth Leaders ETF CAFG | 0.37% | 111.9K | 0.59% |
| 10 | Applied Finance IVS US SMID ETF IVSS | 0.37% | 46.7K | 0.59% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
20.4K
Cash buys
—
Cash sales
—
Net activity
-20,362
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 20,362 | 9.11 | 185.5K | 446,238 | D | ↗ |
| 2026-03-17 | Guiheen Lawrence P. | Director | G-Gift | D | Common Stock | 30,000 | 0.00 | — | 105,520 | D | ↗ |
| 2026-03-16 | Grossman Adam S | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 5.40 | 81.0K | 2,133,777 | D | ↗ |
| 2026-03-13 | Guiheen Lawrence P. | Director | M-Exempt | A | Common Stock | 30,000 | 3.66 | 109.8K | 135,520 | D | ↗ |
| 2026-03-09 | Kestenberg-Messina Kaitlin M. | Officer | M-Exempt | A | Common Stock | 2,500 | 5.00 | 12.5K | 469,100 | D | ↗ |
| 2026-03-07 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 4,235 | 15.39 | 65.2K | 557,866 | D | ↗ |
| 2026-03-07 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 29,513 | 15.39 | 454.2K | 2,118,777 | D | ↗ |
| 2026-03-06 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 10,059 | 15.39 | 154.8K | 562,101 | D | ↗ |
| 2026-03-06 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 56,438 | 15.39 | 868.6K | 2,148,290 | D | ↗ |
| 2026-03-06 | ELMS STEVE | Director | P-Purchase | A | Common Stock | 7,000 | 15.39 | 107.7K | 2,045,730 | I | ↗ |
| 2026-03-05 | ELMS STEVE | Director | P-Purchase | A | Common Stock | 7,000 | 15.67 | 109.7K | 2,038,730 | I | ↗ |
| 2026-02-26 | Kohler Terry | Officer | — | — | Common Stock | 0 | 0.00 | — | 58,019 | D | ↗ |
| 2026-02-26 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 54,858 | 15.18 | 832.7K | 2,204,728 | D | ↗ |
| 2026-02-19 | Tade Brad L. | Officer | F-InKind | D | Common Stock | 6,479 | 16.32 | 105.7K | 232,940 | D | ↗ |
| 2026-02-19 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 8,161 | 16.32 | 133.2K | 572,160 | D | ↗ |
| 2026-02-19 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 24,793 | 16.32 | 404.6K | 2,259,586 | D | ↗ |
| 2026-02-17 | Grossman Adam S | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 5.40 | 81.0K | 2,305,379 | D | ↗ |
| 2026-02-09 | Salas Eduardo Rene | Director | A-Award | A | Stock Option (Right to Buy) | 17,730 | 16.37 | 290.2K | 17,730 | D | ↗ |
| 2026-02-09 | Kestenberg-Messina Kaitlin M. | Officer | A-Award | A | Common Stock | 91,631 | 0.00 | — | 580,321 | D | ↗ |
| 2026-02-09 | KWON YOUNG | Director | A-Award | A | Stock Option (Right to Buy) | 17,730 | 16.37 | 290.2K | 17,730 | D | ↗ |
| 2026-02-09 | Guiheen Lawrence P. | Director | A-Award | A | Stock Option (Right to Buy) | 17,730 | 16.37 | 290.2K | 17,730 | D | ↗ |
| 2026-02-09 | Grossman Jerrold B | Director | A-Award | A | Stock Option (Right to Buy) | 17,730 | 16.37 | 290.2K | 17,730 | D | ↗ |
| 2026-02-09 | Grossman Adam S | Director / Officer | A-Award | A | Stock Option (right to buy) | 444,711 | 16.37 | 7.28M | 444,711 | D | ↗ |
| 2026-02-09 | FINGER ALISON CECILY | Director | A-Award | A | Common Stock | 10,690 | 0.00 | — | 45,619 | D | ↗ |
| 2026-02-09 | ELMS STEVE | Director | A-Award | A | Stock Option (Right to Buy) | 17,730 | 16.37 | 290.2K | 17,730 | D | ↗ |
| 2025-12-15 | Grossman Adam S | Director / Officer | S-Sale | D | Common Stock | 6,000 | 19.79 | 118.7K | 2,007,850 | D | ↗ |
| 2025-11-19 | Grossman Adam S | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 5.40 | 81.0K | 2,034,850 | D | ↗ |
| 2025-10-24 | Grossman Adam S | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 15,000 | 5.40 | 81.0K | 750,950 | D | ↗ |
| 2025-09-15 | Grossman Adam S | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 5.40 | 81.0K | 2,046,850 | D | ↗ |
| 2025-08-15 | Grossman Adam S | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 5.40 | 81.0K | 2,052,850 | D | ↗ |
| 2025-07-30 | Kestenberg-Messina Kaitlin M. | Officer | M-Exempt | A | Common Stock | 2,500 | 8.98 | 22.5K | 489,898 | D | ↗ |
| 2025-07-24 | Tade Brad L. | Officer | F-InKind | D | Common Stock | 7,123 | 17.31 | 123.3K | 239,419 | D | ↗ |
| 2025-07-24 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 3,027 | 17.31 | 52.4K | 487,398 | D | ↗ |
| 2025-07-15 | Grossman Adam S | Director / Officer | S-Sale | D | Common Stock | 15,000 | 18.66 | 279.9K | 2,043,850 | D | ↗ |
| 2025-06-26 | Tade Brad L. | Officer | F-InKind | D | Common Stock | 9,838 | 18.40 | 181.0K | 246,542 | D | ↗ |
| 2025-06-16 | Grossman Adam S | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 5.40 | 81.0K | 2,064,850 | D | ↗ |
| 2025-06-16 | ELMS STEVE | Director | S-Sale | D | Common Stock | 194,749 | 20.24 | 3.94M | 87,330 | D | ↗ |
| 2025-06-13 | ELMS STEVE | Director | M-Exempt | D | Stock Option (Right to Buy) | 55,000 | 2.35 | 129.3K | 0 | D | ↗ |
| 2025-06-12 | ELMS STEVE | Director | S-Sale | D | Common Stock | 92,941 | 21.69 | 2.02M | 2,031,730 | I | ↗ |
| 2025-06-09 | Guiheen Lawrence P. | Director | S-Sale | D | Common Stock | 20,000 | 20.96 | 419.2K | 94,830 | D | ↗ |
| 2025-06-09 | Grossman Jerrold B | Director | M-Exempt | A | Common Stock | 10,000 | 5.00 | 50.0K | 488,194 | D | ↗ |
| 2025-05-22 | Guiheen Lawrence P. | Director | M-Exempt | A | Common Stock | 1,221 | 5.96 | 7.3K | 116,051 | D | ↗ |
| 2025-05-21 | Guiheen Lawrence P. | Director | S-Sale | D | Common Stock | 7,779 | 20.32 | 158.1K | 114,830 | D | ↗ |
| 2025-05-15 | Grossman Adam S | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 15,000 | 5.40 | 81.0K | 825,950 | D | ↗ |
| 2025-04-15 | Grossman Adam S | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 5.40 | 81.0K | 2,076,850 | D | ↗ |
| 2025-04-01 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 18,920 | 19.42 | 367.4K | 490,425 | D | ↗ |
| 2025-03-19 | Grossman Adam S | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 5.40 | 81.0K | 2,082,850 | D | ↗ |
| 2025-03-07 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 3,935 | 17.02 | 67.0K | 509,345 | D | ↗ |
| 2025-03-07 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 29,513 | 17.02 | 502.3K | 2,067,850 | D | ↗ |
| 2025-03-06 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 8,881 | 16.91 | 150.2K | 513,280 | D | ↗ |
| 2025-03-06 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 56,438 | 16.91 | 954.4K | 2,097,363 | D | ↗ |
| 2025-02-26 | Tade Brad L. | Officer | F-InKind | D | Common Stock | 5,280 | 15.78 | 83.3K | 256,380 | D | ↗ |
| 2025-02-26 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 54,867 | 15.78 | 865.8K | 2,153,801 | D | ↗ |
| 2025-02-25 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 1,855 | 15.44 | 28.6K | 522,161 | D | ↗ |
| 2025-02-25 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 18,018 | 15.44 | 278.2K | 2,208,668 | D | ↗ |
| 2025-02-19 | Tade Brad L. | Officer | A-Award | A | Stock Option (right to buy) | 93,023 | 16.07 | 1.49M | 93,023 | D | ↗ |
| 2025-02-19 | Salas Eduardo Rene | Director | A-Award | A | Common Stock | 10,889 | 0.00 | — | 10,889 | D | ↗ |
| 2025-02-19 | Kestenberg-Messina Kaitlin M. | Officer | A-Award | A | Stock Option (right to buy) | 116,279 | 16.07 | 1.87M | 116,279 | D | ↗ |
| 2025-02-19 | KWON YOUNG | Director | A-Award | A | Stock Option (right to buy) | 16,279 | 16.07 | 261.6K | 16,279 | D | ↗ |
| 2025-02-19 | Guiheen Lawrence P. | Director | A-Award | A | Stock Option (right to buy) | 16,279 | 16.07 | 261.6K | 16,279 | D | ↗ |
| 2025-02-19 | Grossman Jerrold B | Director | A-Award | A | Common Stock | 10,889 | 0.00 | — | 478,194 | D | ↗ |
| 2025-02-19 | Grossman Adam S | Director / Officer | A-Award | A | Common Stock | 252,022 | 0.00 | — | 2,226,686 | D | ↗ |
| 2025-02-19 | FINGER ALISON CECILY | Director | A-Award | A | Stock Option (right to buy) | 16,279 | 16.07 | 261.6K | 16,279 | D | ↗ |
| 2025-02-19 | ELMS STEVE | Director | A-Award | A | Stock Option (Right to Buy) | 16,279 | 16.07 | 261.6K | 16,279 | D | ↗ |
| 2025-01-30 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 3,355 | 16.10 | 54.0K | 446,232 | D | ↗ |
| 2024-12-31 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 1,854 | 17.15 | 31.8K | 444,587 | D | ↗ |
| 2024-12-31 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 14,343 | 17.15 | 246.0K | 1,974,664 | D | ↗ |
| 2024-12-30 | Salas Eduardo Rene | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-27 | ELMS STEVE | Director | M-Exempt | A | Common Stock | 9,000 | 10.80 | 97.2K | 2,124,671 | I | ↗ |
| 2024-11-22 | Tade Brad L. | Officer | S-Sale | D | Common Stock | 15,000 | 21.15 | 317.3K | 199,433 | D | ↗ |
| 2024-11-22 | Grossman Adam S | Director / Officer | S-Sale | D | Common Stock | 48,967 | 21.10 | 1.03M | 1,989,007 | D | ↗ |
| 2024-09-30 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 2,647 | 19.99 | 52.9K | 446,441 | D | ↗ |
| 2024-09-30 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 21,752 | 19.99 | 434.8K | 2,037,974 | D | ↗ |
| 2024-09-09 | Guiheen Lawrence P. | Director | M-Exempt | A | Common Stock | 9,000 | 10.80 | 97.2K | 162,941 | — | ↗ |
| 2024-08-30 | Kestenberg-Messina Kaitlin M. | Officer | M-Exempt | D | Common Stock | 4,375 | 2.59 | 11.3K | 0 | — | ↗ |
| 2024-08-29 | Grossman Jerrold B | Director | S-Sale | D | Common Stock | 136,861 | 17.27 | 2.36M | 467,305 | — | ↗ |
| 2024-08-27 | Grossman Adam S | Director / Officer | M-Exempt | D | Common Stock | 47,396 | 2.92 | 138.2K | 0 | — | ↗ |
| 2024-08-26 | Grossman Adam S | Director / Officer | M-Exempt | D | Common Stock | 60,000 | 10.80 | 648.0K | 0 | — | ↗ |
| 2024-08-23 | KWON YOUNG | Director | S-Sale | D | Common Stock | 60,000 | 18.26 | 1.10M | 241,441 | — | ↗ |
| 2024-07-24 | Tade Brad L. | Officer | A-Award | A | Common Stock | 72,400 | 0.00 | — | 214,433 | — | ↗ |
| 2024-07-24 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 2,502 | 13.58 | 34.0K | 449,088 | — | ↗ |
| 2024-06-30 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 2,085 | 11.18 | 23.3K | 451,590 | — | ↗ |
| 2024-06-30 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 21,752 | 11.18 | 243.2K | 2,059,726 | — | ↗ |
| 2024-06-14 | Grossman Adam S | Director / Officer | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 2,181,475 | — | ↗ |
| 2024-04-01 | Kestenberg-Messina Kaitlin M. | Officer | — | D | Stock Option (Right to Buy) | 5,000 | 10.80 | 54.0K | 0 | — | ↗ |
| 2024-03-31 | Kestenberg-Messina Kaitlin M. | Officer | F-InKind | D | Common Stock | 2,085 | 6.60 | 13.8K | 112,190 | — | ↗ |
| 2024-03-31 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 21,752 | 6.60 | 143.6K | 2,651,475 | — | ↗ |
| 2024-03-19 | ELMS STEVE | Director | S-Sale | D | Common Stock | 411,829 | 6.08 | 2.50M | 2,115,671 | — | ↗ |
| 2024-03-18 | ELMS STEVE | Director | S-Sale | D | Common Stock | 49,887 | 6.01 | 299.8K | 2,527,500 | — | ↗ |
| 2024-03-15 | ELMS STEVE | Director | S-Sale | D | Common Stock | 183,008 | 6.01 | 1.10M | 2,577,387 | — | ↗ |
| 2024-03-14 | ELMS STEVE | Director | S-Sale | D | Common Stock | 448,276 | 6.05 | 2.71M | 2,760,395 | — | ↗ |
| 2024-03-13 | ELMS STEVE | Director | S-Sale | D | Common Stock | 407,000 | 6.21 | 2.53M | 3,208,671 | — | ↗ |
| 2024-03-07 | LENZ BRIAN | Officer | F-InKind | D | Common Stock | 16,965 | 6.16 | 104.5K | 703,002 | — | ↗ |
| 2024-03-07 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 28,763 | 6.16 | 177.2K | 2,673,227 | — | ↗ |
| 2024-03-06 | LENZ BRIAN | Officer | F-InKind | D | Common Stock | 16,677 | 6.12 | 102.1K | 719,967 | — | ↗ |
| 2024-03-06 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 55,003 | 6.12 | 336.6K | 2,701,990 | — | ↗ |
| 2024-02-29 | LENZ BRIAN | Officer | F-InKind | D | Common Stock | 4,935 | 5.36 | 26.5K | 736,644 | — | ↗ |
| 2024-02-29 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 9,588 | 5.36 | 51.4K | 2,756,993 | — | ↗ |
| 2024-02-26 | KWON YOUNG | Director | A-Award | A | Stock Option (right to buy) | 37,541 | 5.40 | 202.7K | 37,541 | — | ↗ |
| 2024-02-26 | Guiheen Lawrence P. | Director | A-Award | A | Stock Option (right to buy) | 37,541 | 5.40 | 202.7K | 37,541 | — | ↗ |
| 2024-02-26 | Grossman Jerrold B | Director | A-Award | A | Common Stock | 24,040 | 0.00 | — | 467,305 | — | ↗ |
| 2024-02-26 | Grossman Adam S | Director / Officer | A-Award | A | Stock Option (right to buy) | 870,950 | 5.40 | 4.70M | 870,950 | — | ↗ |
| 2024-02-26 | Fong Bryant | Director | A-Award | A | Stock Option (right to buy) | 37,541 | 5.40 | 202.7K | 37,541 | — | ↗ |
| 2024-02-26 | FINGER ALISON CECILY | Director | A-Award | A | Stock Option (right to buy) | 37,541 | 5.40 | 202.7K | 37,541 | — | ↗ |
| 2024-02-26 | ELMS STEVE | Director | A-Award | A | Stock Option (right to buy) | 37,541 | 5.40 | 202.7K | 37,541 | — | ↗ |
| 2024-02-25 | LENZ BRIAN | Officer | F-InKind | D | Common Stock | 8,257 | 5.26 | 43.4K | 741,579 | — | ↗ |
| 2024-02-25 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 22,457 | 5.26 | 118.1K | 2,208,853 | — | ↗ |
| 2023-12-31 | LENZ BRIAN | Officer | F-InKind | D | Common Stock | 16,908 | 4.52 | 76.4K | 749,836 | — | ↗ |
| 2023-12-31 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 23,057 | 4.52 | 104.2K | 2,231,310 | — | ↗ |
| 2023-09-30 | LENZ BRIAN | Officer | F-InKind | D | Common Stock | 15,268 | 3.58 | 54.7K | 766,744 | — | ↗ |
| 2023-09-30 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 18,718 | 3.58 | 67.0K | 2,254,367 | — | ↗ |
| 2023-09-28 | FINGER ALISON CECILY | Director | — | D | Stock Option (Right to Buy) | 98,870 | 3.54 | 350.0K | 0 | — | ↗ |
| 2023-08-30 | Grossman Jerrold B | Director | P-Purchase | A | Common Stock | 130,000 | 3.71 | 482.1K | 443,265 | — | ↗ |
| 2023-08-24 | KWON YOUNG | Director | P-Purchase | A | Common Stock | 25,000 | 3.90 | 97.5K | 277,401 | — | ↗ |
| 2023-08-22 | Fong Bryant | Director | S-Sale | D | Common Stock | 1,433,304 | 3.87 | 5.54M | 0 | — | ↗ |
| 2023-08-18 | Grossman Adam S | Director / Officer | S-Sale | D | Common Stock | 250,000 | 4.15 | 1.04M | 2,273,085 | — | ↗ |
| 2023-08-16 | LENZ BRIAN | Officer | S-Sale | D | Common Stock | 178,184 | 4.45 | 793.4K | 782,013 | — | ↗ |
| 2023-08-16 | Grossman Adam S | Director / Officer | S-Sale | D | Common Stock | 3 | 4.39 | 13.16 | 2,523,085 | — | ↗ |
| 2023-08-15 | LENZ BRIAN | Officer | M-Exempt | A | Common Stock | 97,395 | 1.67 | 162.6K | 879,408 | — | ↗ |
| 2023-08-15 | Grossman Adam S | Director / Officer | M-Exempt | D | Common Stock | 350,000 | 3.71 | 1.30M | 0 | — | ↗ |
| 2023-06-30 | LENZ BRIAN | Officer | F-InKind | D | Common Stock | 15,268 | 3.69 | 56.3K | 993,591 | — | ↗ |
| 2023-06-30 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 20,051 | 3.69 | 74.0K | 2,523,085 | — | ↗ |
| 2023-03-31 | LENZ BRIAN | Officer | F-InKind | D | Common Stock | 15,469 | 3.31 | 51.2K | 1,008,858 | — | ↗ |
| 2023-03-31 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 17,853 | 3.31 | 59.1K | 2,543,139 | — | ↗ |
| 2023-03-07 | LENZ BRIAN | Officer | F-InKind | D | Common Stock | 16,965 | 3.40 | 57.7K | 1,024,327 | — | ↗ |
| 2023-03-07 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 23,607 | 3.40 | 80.3K | 2,560,992 | — | ↗ |
| 2023-03-06 | LENZ BRIAN | Officer | A-Award | A | Employee Stock Option (right to buy) | 270,345 | 3.35 | 905.7K | 270,345 | — | ↗ |
| 2023-03-06 | KWON YOUNG | Director | A-Award | A | Employee Stock Option (right to buy) | 51,630 | 3.35 | 173.0K | 51,630 | — | ↗ |
| 2023-03-06 | Guiheen Lawrence P. | Director | A-Award | A | Employee Stock Option (right to buy) | 51,630 | 3.35 | 173.0K | 51,630 | — | ↗ |
| 2023-03-06 | Grossman Jerrold B | Director | A-Award | A | Common Stock | 25,815 | 0.00 | — | 313,265 | — | ↗ |
| 2023-03-06 | Grossman Adam S | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,147,385 | 3.35 | 3.84M | 1,147,385 | — | ↗ |
| 2023-03-06 | Fong Bryant | Director | A-Award | A | Employee Stock Option (right to buy) | 51,630 | 3.35 | 173.0K | 51,630 | — | ↗ |
| 2023-03-06 | ELMS STEVE | Director | A-Award | A | Employee Stock Option (right to buy) | 51,630 | 3.35 | 173.0K | 51,630 | — | ↗ |
| 2023-03-06 | DEMSKI MARTHA J | Director | A-Award | A | Employee Stock Option (right to buy) | 51,630 | 3.35 | 173.0K | 51,630 | — | ↗ |
| 2023-02-28 | LENZ BRIAN | Officer | F-InKind | D | Common Stock | 5,000 | 3.55 | 17.8K | 906,117 | — | ↗ |
| 2023-02-28 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 7,507 | 3.55 | 26.6K | 2,010,904 | — | ↗ |
| 2023-02-25 | LENZ BRIAN | Officer | F-InKind | D | Common Stock | 7,927 | 3.42 | 27.1K | 911,117 | — | ↗ |
| 2023-02-25 | Grossman Adam S | Director / Officer | F-InKind | D | Common Stock | 14,412 | 3.42 | 49.3K | 2,018,411 | — | ↗ |
| 2023-01-04 | LENZ BRIAN | Director | F-InKind | D | Common Stock | 114,222 | 3.87 | 442.0K | 920,603 | — | ↗ |
| 2023-01-04 | Grossman Adam S | Director | F-InKind | D | Common Stock | 166,867 | 3.87 | 645.8K | 2,036,841 | — | ↗ |
| 2022-12-09 | LENZ BRIAN | Director | P-Purchase | A | Common Stock | 6,993 | 2.86 | 20.0K | 1,034,825 | — | ↗ |
| 2022-12-09 | Grossman Adam S | Director | P-Purchase | A | Common Stock | 14,983 | 2.86 | 42.9K | 2,203,708 | — | ↗ |
| 2022-09-30 | LENZ BRIAN | Director | F-InKind | D | Common Stock | 73,678 | 2.43 | 179.0K | 1,027,832 | — | ↗ |
| 2022-09-30 | Grossman Adam S | Director | F-InKind | D | Common Stock | 101,315 | 2.43 | 246.2K | 2,188,725 | — | ↗ |
| 2022-05-11 | LENZ BRIAN | Director | F-InKind | D | Common Stock | 51,965 | 1.43 | 74.3K | 1,101,510 | — | ↗ |
| 2022-05-11 | Grossman Adam S | Director | F-InKind | D | Common Stock | 70,004 | 1.43 | 100.1K | 2,290,040 | — | ↗ |
| 2022-03-23 | LENZ BRIAN | Director | F-InKind | D | Common Stock | 37,178 | 1.46 | 54.3K | 1,153,475 | — | ↗ |
| 2022-03-23 | Grossman Adam S | Director | F-InKind | D | Common Stock | 50,539 | 1.46 | 73.8K | 2,360,044 | — | ↗ |
| 2022-03-07 | LENZ BRIAN | Officer | A-Award | A | Employee Stock Option (right to buy) | 275,000 | 1.67 | 459.3K | 275,000 | — | ↗ |
| 2022-03-07 | KWON YOUNG | Director | A-Award | A | Common Stock | 26,586 | 0.00 | — | 226,586 | — | ↗ |
| 2022-03-07 | Guiheen Lawrence P. | Director | A-Award | A | Employee Stock Option (right to buy) | 53,172 | 0.00 | — | 53,172 | — | ↗ |
| 2022-03-07 | Grossman Jerrold B | Director | A-Award | A | Employee Stock Option (right to buy) | 53,172 | 0.00 | — | 53,172 | — | ↗ |
| 2022-03-07 | Grossman Adam S | Director | A-Award | A | Employee Stock Option (right to buy) | 600,000 | 0.00 | — | 600,000 | — | ↗ |
| 2022-03-07 | Fong Bryant | Director | A-Award | A | Common Stock | 26,586 | 0.00 | — | 34,086 | — | ↗ |
| 2022-03-07 | ELMS STEVE | Director | A-Award | A | Common Stock | 26,586 | 0.00 | — | 26,586 | — | ↗ |
| 2022-03-07 | DEMSKI MARTHA J | Director | A-Award | A | Common Stock | 26,586 | 0.00 | — | 30,786 | — | ↗ |
| 2021-10-25 | LENZ BRIAN | Officer | P-Purchase | A | Common Stock | 30,000 | 1.00 | 30.0K | 1,065,501 | — | ↗ |
| 2021-10-25 | KWON YOUNG | Director | P-Purchase | A | Common Stock | 100,000 | 1.00 | 100.0K | 200,000 | — | ↗ |
| 2021-10-25 | Grossman Jerrold B | Director | P-Purchase | A | Common Stock | 100,000 | 1.00 | 100.0K | 260,864 | — | ↗ |
| 2021-10-25 | Grossman Adam S | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 1.00 | 100.0K | 2,137,616 | — | ↗ |
| 2021-10-15 | KWON YOUNG | Director | A-Award | A | Stock Option (right to buy) | 93,500 | 1.10 | 102.9K | 93,500 | — | ↗ |
| 2021-09-30 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 137,495 | 1.12 | 154.0K | 13,262,375 | — | ↗ |
| 2021-09-29 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 82,505 | 1.16 | 95.7K | 13,399,870 | — | ↗ |
| 2021-09-29 | LENZ BRIAN | Officer | A-Award | A | Common Stock | 495,000 | 0.00 | — | 630,501 | — | ↗ |
| 2021-09-29 | Grossman Adam S | Director / Officer | A-Award | A | Common Stock | 907,500 | 0.00 | — | 1,295,116 | — | ↗ |
| 2021-09-28 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 40,603 | 1.22 | 49.5K | 13,482,375 | — | ↗ |
| 2021-09-27 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 250,000 | 1.23 | 307.5K | 13,522,978 | — | ↗ |
| 2021-09-24 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 250,000 | 1.26 | 315.0K | 13,772,978 | — | ↗ |
| 2021-09-23 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 780,000 | 1.27 | 990.6K | 14,022,978 | — | ↗ |
| 2021-08-19 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 350,352 | 1.24 | 434.4K | 14,802,978 | — | ↗ |
| 2021-08-18 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 552,380 | 1.29 | 712.6K | 15,153,330 | — | ↗ |
| 2021-08-17 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 879,092 | 1.35 | 1.19M | 15,705,710 | — | ↗ |
| 2021-02-25 | Mond James | Officer | A-Award | A | Common Stock | 64,361 | 0.00 | — | 137,535 | — | ↗ |
| 2021-02-25 | LENZ BRIAN | Officer | A-Award | A | Employee Stock Option (right to buy) | 139,000 | 2.35 | 326.7K | 139,000 | — | ↗ |
| 2021-02-25 | Guiheen Lawrence P. | Director | A-Award | A | Stock Option (right to buy) | 55,000 | 2.35 | 129.3K | 55,000 | — | ↗ |
| 2021-02-25 | Grossman Jerrold B | Director | A-Award | A | Stock Option (right to buy) | 55,000 | 2.35 | 129.3K | 55,000 | — | ↗ |
| 2021-02-25 | Grossman Adam S | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 458,700 | 2.35 | 1.08M | 458,700 | — | ↗ |
| 2021-02-25 | Fong Bryant | Director | A-Award | A | Stock Option (right to buy) | 55,000 | 2.35 | 129.3K | 55,000 | — | ↗ |
| 2021-02-25 | ELMS STEVE | Director | A-Award | A | Stock Option (right to buy) | 55,000 | 2.35 | 129.3K | 55,000 | — | ↗ |
| 2021-02-25 | DEMSKI MARTHA J | Director | A-Award | A | Stock Option (right to buy) | 55,000 | 2.35 | 129.3K | 55,000 | — | ↗ |
| 2020-09-11 | DEMSKI MARTHA J | Director | P-Purchase | A | Common Stock | 2,200 | 2.29 | 5.0K | 4,200 | — | ↗ |
| 2020-09-10 | Grossman Jerrold B | Director | P-Purchase | A | Common Stock | 5,000 | 2.22 | 11.1K | 160,864 | — | ↗ |
| 2020-09-08 | Mond James | Officer | P-Purchase | A | Common Stock | 4,000 | 2.20 | 8.8K | 73,174 | — | ↗ |
| 2020-09-08 | Grossman Adam S | Director / Officer | P-Purchase | A | Common Stock | 4,000 | 2.24 | 9.0K | 176,098 | — | ↗ |
| 2020-08-21 | Grossman Jerrold B | Director | P-Purchase | A | Common Stock | 300 | 2.62 | 786.00 | 155,864 | — | ↗ |
| 2020-08-13 | DEMSKI MARTHA J | Director | P-Purchase | A | Common Stock | 2,000 | 2.88 | 5.8K | 2,000 | — | ↗ |
| 2020-08-12 | Grossman Jerrold B | Director | P-Purchase | A | Common Stock | 5,000 | 2.90 | 14.5K | 150,564 | — | ↗ |
| 2020-08-11 | LENZ BRIAN | Officer | P-Purchase | A | Common Stock | 4,000 | 2.97 | 11.9K | 76,142 | — | ↗ |
| 2020-08-11 | Grossman Adam S | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 2.97 | 3.0K | 172,098 | — | ↗ |
| 2020-08-10 | Mond James | Officer | P-Purchase | A | Common Stock | 2,000 | 2.88 | 5.8K | 69,174 | — | ↗ |
| 2020-08-10 | Grossman Adam S | Director / Officer | P-Purchase | A | Common Stock | 10 | 3.06 | 30.60 | 166,108 | — | ↗ |
| 2020-06-18 | DEMSKI MARTHA J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-03-19 | PERCEPTIVE ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 500,000 | 2.10 | 1.05M | 16,584,802 | — | ↗ |
| 2020-02-28 | RICHMAN ERIC I | Director | A-Award | A | Employee Stock Option (right to buy) | 15,000 | 2.92 | 43.7K | 15,000 | — | ↗ |
| 2020-02-28 | Mond James | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 62,174 | — | ↗ |
| 2020-02-28 | LENZ BRIAN | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 2.92 | 291.5K | 100,000 | — | ↗ |
| 2020-02-28 | Guiheen Lawrence P. | Director | A-Award | A | Employee Stock Option (right to buy) | 15,000 | 2.92 | 43.7K | 15,000 | — | ↗ |
| 2020-02-28 | Grossman Jerrold B | Director | A-Award | A | Employee Stock Option (right to buy) | 15,000 | 2.92 | 43.7K | 15,000 | D | ↗ |
| 2020-02-28 | Grossman Adam S | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 166,098 | — | ↗ |
| 2020-02-28 | GOLDSTEIN DOV A MD | Director | A-Award | A | Employee Stock Option (right to buy) | 15,000 | 2.92 | 43.7K | 15,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
277.0K
Shares Outstanding
232.32M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Adam S. Grossman President, Chief Executive Officer and Director | 925.0K | — | 4.05M | 4.05M | 1.16M | 56.1K | 10.24M | 79.12% | ↗ |
| 2 | 2025 | Kaitlin Kestenberg Chief Operating Officer & Senior Vice President, Compliance | 575.0K | — | 1.25M | 1.25M | 359.4K | 54.3K | 3.49M | 71.66% | ↗ |
| 3 | 2025 | Brad L. Tade Former Executive Vice President and Chief Financial Officer | 500.0K | — | 1,000.0K | 1,000.0K | 250.0K | 73.6K | 2.82M | 70.83% | ↗ |
| 4 | 2025 | Paul Terence Kohler, Jr. Current Chief Financial Officer and Treasurer | 19.2K | — | 1.12M | 1.12M | 15.8K | 12.0K | 2.30M | 97.95% | ↗ |
| 5 | 2024 | Adam S. Grossman President, Chief Executive Officer and Director | 800.0K | — | 3.01M | 3.04M | 1.02M | 44.7K | 7.92M | 76.45% | ↗ |
| 6 | 2024 | Kaitlin Kestenberg Chief Operating Officer & Senior Vice President of Compliance | 433.1K | — | 1.26M | 1.27M | 345.0K | 37.7K | 3.34M | 75.57% | ↗ |
| 7 | 2024 | Kaitlin Kestenberg Chief Operating Officer & Senior Vice President, Compliance | 433.1K | — | 1.26M | 1.27M | 345.0K | 37.7K | 3.34M | 75.57% | ↗ |
| 8 | 2024 | Brad L. Tade Former Executive Vice President and Chief Financial Officer | 374.8K | — | 1.25M | 1.00M | 254.5K | 51.7K | 2.94M | 76.81% | ↗ |
| 9 | 2024 | Brad L. Tade Chief Financial Officer and Treasurer | 374.8K | — | 1.25M | 1.00M | 254.5K | 51.7K | 2.94M | 76.81% | ↗ |
| 10 | 2024 | Brian Lenz Former Executive Vice President and Chief Financial Officer | 127.9K | — | — | — | — | 554.9K | 682.8K | 0.00% | ↗ |
| 11 | 2023 | Adam S. Grossman President, Chief Executive Officer and Director | 750.0K | 793.1K | 1.92M | 2.53M | — | 46.8K | 6.04M | 73.68% | ↗ |
| 12 | 2023 | Adam S. Grossman Director, President, Chief Executive Officer and Interim Chief Financial Officer | 750.0K | 793.1K | 1.92M | 2.53M | — | 46.8K | 6.04M | 73.68% | ↗ |
| 13 | 2023 | Brian Lenz Former Executive Vice President and Chief Financial Officer | 475.0K | 334.9K | 452.8K | 595.6K | — | 107.0K | 1.97M | 53.35% | ↗ |
| 14 | 2022 | Adam S. Grossman Director, President and Chief Executive Officer | 636.5K | 837.4K | 501.0K | 629.1K | — | 45.5K | 2.65M | 42.65% | ↗ |
| 15 | 2022 | Adam S. Grossman President, Chief Executive Officer and Director | 636.5K | 837.4K | 501.0K | 629.1K | — | 45.5K | 2.65M | 42.65% | ↗ |
| 16 | 2022 | Adam S. Grossman Director, President, Chief Executive Officer and Interim Chief Financial Officer | 636.5K | 837.4K | 501.0K | 629.1K | — | 45.5K | 2.65M | 42.65% | ↗ |
| 17 | 2022 | Brian Lenz Former Executive Vice President and Chief Financial Officer | 445.6K | 471.8K | 229.6K | 288.3K | — | 165.8K | 1.60M | 32.35% | ↗ |
| 18 | 2022 | Brian Lenz Executive Vice President and Chief Financial Officer | 445.6K | 471.8K | 229.6K | 288.3K | — | 165.8K | 1.60M | 32.35% | ↗ |
| 19 | 2021 | Adam S. Grossman Director, President and Chief Executive Officer | 618.0K | 731.1K | 2.29M | 673.9K | — | 43.3K | 4.36M | 68.07% | ↗ |
| 20 | 2021 | Brian Lenz Executive Vice President and Chief Financial Officer | 432.6K | 420.3K | 1.15M | 204.2K | — | 163.3K | 2.37M | 57.06% | ↗ |
| 21 | 2021 | Dr. James Mond Former Executive Vice President, Chief Scientific Officer and Chief Medical Officer | 216.5K | — | 129.3K | 204.2K | — | 544.1K | 1.09M | 30.48% | ↗ |
| 22 | 2020 | Adam S. Grossman Director, President and Chief Executive Officer | 600.0K | 486.0K | 291.5K | 544.5K | — | 40.1K | 1.96M | 42.61% | ↗ |
| 23 | 2020 | Dr. James Mond Executive Vice President, Chief Scientific Officer and Chief Medical Officer | 440.0K | 233.2K | 116.6K | 167.5K | — | 238.0K | 1.20M | 23.77% | ↗ |
| 24 | 2020 | Dr. James Mond Former Executive Vice President, Chief Scientific Officer and Chief Medical Officer | 440.0K | 233.2K | 116.6K | 167.5K | — | 238.0K | 1.20M | 23.77% | ↗ |
| 25 | 2020 | Brian Lenz Executive Vice President and Chief Financial Officer | 420.0K | 222.6K | 116.6K | 167.5K | — | 160.3K | 1.09M | 26.14% | ↗ |
| 26 | 2019 | Adam S. Grossman Director, President and Chief Executive Officer | 536.0K | 368.5K | — | 760.9K | — | 36.7K | 1.70M | 44.70% | ↗ |
| 27 | 2019 | Dr. James Mond Executive Vice President, Chief Scientific Officer and Chief Medical Officer | 415.0K | 207.5K | — | 380.4K | — | 234.5K | 1.24M | 30.74% | ↗ |
| 28 | 2019 | Brian Lenz Executive Vice President and Chief Financial Officer | 390.0K | 195.0K | — | 380.4K | — | 156.7K | 1.12M | 33.90% | ↗ |
| 29 | 2018 | Adam S. Grossman Director, President and Chief Executive Officer | 536.0K | 215.2K | — | 728.5K | — | 73.6K | 1.55M | 46.90% | ↗ |
| 30 | 2018 | Dr. James Mond Executive Vice President, Chief Scientific Officer and Chief Medical Officer | 401.8K | 117.3K | — | 312.2K | — | 214.1K | 1.05M | 29.87% | ↗ |
| 31 | 2018 | Brian Lenz Executive Vice President and Chief Financial Officer | 366.8K | 107.1K | — | 312.2K | — | 154.0K | 940.1K | 33.21% | ↗ |
| 32 | 2017 | Adam S. Grossman Director, President and Chief Executive Officer | 494.4K | 222.2K | — | 1.44M | — | 508.1K | 2.66M | 53.96% | ↗ |
| 33 | 2017 | Dr. James Mond Executive Vice President, Chief Scientific Officer and Chief Medical Officer | 360.5K | 127.7K | — | 595.8K | — | 86.2K | 1.17M | 50.92% | ↗ |
| 34 | 2017 | Brian Lenz Vice President and Chief Financial Officer | 360.5K | 158.7K | — | 486.8K | — | 90.0K | 1.10M | 44.42% | ↗ |
| 35 | 2017 | Brian Lenz Executive Vice President and Chief Financial Officer | 360.5K | 158.7K | — | 486.8K | — | 90.0K | 1.10M | 44.42% | ↗ |
| 36 | 2016 | Adam S. Grossman Director, President and Chief Executive Officer | 492.8K | 212.4K | — | 51.8K | — | 8.0K | 765.0K | 6.78% | ↗ |
| 37 | 2016 | Dr. James Mond Executive Vice President, Chief Scientific Officer and Chief Medical Officer | 360.2K | 122.5K | — | 20.6K | — | 8.0K | 511.2K | 4.03% | ↗ |
| 38 | 2016 | Brian Lenz Vice President and Chief Financial Officer | 360.2K | 122.5K | — | 17.6K | — | 8.0K | 508.2K | 3.45% | ↗ |
| 39 | 2015 | Adam S. Grossman Director, President and Chief Executive Officer | 476.5K | 211.2K | — | 547.9K | — | 8.0K | 1.24M | 44.06% | ↗ |
| 40 | 2015 | Dr. James Mond Chief Scientific Officer and Chief Medical Officer | 347.1K | 122.5K | — | 258.8K | — | 8.0K | 736.4K | 35.15% | ↗ |
| 41 | 2015 | Brian Lenz Chief Financial Officer | 346.5K | 122.5K | — | 216.1K | — | 8.0K | 693.1K | 31.18% | ↗ |
| 42 | 2014 | Adam S. Grossman Director, President and Chief Executive Officer | 447.6K | 247.5K | — | 502.7K | — | 7.8K | 1.21M | 41.70% | ↗ |
| 43 | 2014 | Adam S. Grossman Chief Executive Officer | 447.6K | 125.0K | — | — | — | 7.8K | 1.08M | 0.00% | ↗ |
| 44 | 2014 | Brian Lenz Chief Financial Officer | 318.5K | 123.2K | — | 197.6K | — | 7.8K | 647.1K | 30.54% | ↗ |
| 45 | 2014 | Dr. James Mond Chief Scientific Officer and Chief Medical Officer | 323.5K | 125.1K | — | 149.8K | — | 7.8K | 606.2K | 24.71% | ↗ |
| 46 | 2014 | Dr. James Mond Chief Scientific and Medical Officer | 323.5K | 53.6K | — | — | — | 7.8K | 526.8K | 0.00% | ↗ |
| 47 | 2013 | Adam S. Grossman Chief Executive Officer | 359.3K | 125.0K | — | — | — | — | 484.3K | 0.00% | ↗ |
| 48 | 2013 | Adam S. Grossman Chief Executive Officer | 359.3K | 125.0K | — | — | — | — | 484.3K | 0.00% | ↗ |
| 49 | 2013 | Brian Lenz Chief Financial Officer | 264.3K | 79.6K | — | — | — | — | 343.9K | 0.00% | ↗ |
| 50 | 2013 | Dr. James Mond Chief Scientific and Medical Officer | 266.9K | 53.6K | — | — | — | — | 320.5K | 0.00% | ↗ |
| 51 | 2012 | Adam S. Grossman Chief Executive Officer | 332.7K | 100.0K | — | — | — | — | 1.87M | 0.00% | ↗ |
| 52 | 2012 | Dr. James Mond Chief Scientific and Medical Officer | 115.0K | 52.0K | — | — | — | — | 896.9K | 0.00% | ↗ |
| 53 | 2012 | Dr. James Mond Chief Scientific and Medical Officer | 115.0K | 52.0K | — | — | — | — | 896.9K | 0.00% | ↗ |
| 54 | 2012 | Brian Lenz Chief Financial Officer | 168.4K | 77.3K | — | — | — | — | 695.8K | 0.00% | ↗ |
| 55 | 2012 | Brian Lenz Chief Financial Officer | 168.4K | 77.3K | — | — | — | — | 695.8K | 0.00% | ↗ |
| 56 | 2011 | Adam S. Grossman Chief Executive Officer | 218.3K | 50.0K | — | — | — | — | 268.3K | 0.00% | ↗ |
| 57 | 2011 | Brian Lenz Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 58 | 2011 | Dr. James Mond Chief Scientific and Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 59 | 2011 | Brian Lenz | — | — | — | — | — | — | — | — | ↗ |
| 60 | 2011 | Dr. James Mond | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adam S. Grossman | Co-Founder, President, Chief Executive Officer & Director | 2M | male |
| Kaitlin Kestenberg | Chief Operating Officer & Senior Vice President of Compliance | 988.7K | female |
| Brad Tade | Consultant | 823.6K | male |
| Jerrold Grossman | Co-Founder & Vice Chairman of the Board | 90.0K | — |
| Terence Kohler | Chief Financial Officer & Treasurer | 47.0K | male |
| John Hafl | Executive Director of Sales | — | male |
| Michael Goldstein | General Counsel | — | male |
| Skyler Bloom | Senior Director of Business Development & Corporate Strategy | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ADMA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
